GLPwatch
Byetta for Obesity
exenatide · Investigational / off-label
Last updated 2026-05-28 15:46 UTCByetta (exenatide) is not FDA-approved for obesity, and any use for this condition is off-label or investigational. Listed research shows exenatide may lead to weight loss and improve metabolic parameters in some studies, but these findings are not conclusive for approval.
AI summary of the sources below.
| Drug | Byetta (exenatide) |
|---|---|
| Condition | Obesity |
| Approval status | Investigational / off-label |
| Research papers | 50 |
Byetta is not FDA-approved for obesity; the research below reflects investigational or off-label study only.
Research on exenatide for obesity (50)
- DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks.
- Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis.
- Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy.
- Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes.
- Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes.
- Short-term exenatide treatment leads to significant weight loss in a subset of obese women without diabetes.
- Exenatide as a weight-loss therapy in extreme pediatric obesity: a randomized, controlled pilot study.
- Efficacy of exenatide on weight loss, metabolic parameters and pregnancy in overweight/obese polycystic ovary syndrome.
- Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial.
- Exenatide Adjunct to Nicotine Patch Facilitates Smoking Cessation and May Reduce Post-Cessation Weight Gain: A Pilot Randomized Controlled Trial.
- Effects of exenatide vs. metformin on endothelial function in obese patients with pre-diabetes: a randomized trial.
- Dapagliflozin once-daily and exenatide once-weekly dual therapy: A 24-week randomized, placebo-controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetes.
- Preparation of uniform-sized exenatide-loaded PLGA microspheres as long-effective release system with high encapsulation efficiency and bio-stability.
- Exenatide-induced reduction in energy intake is associated with increase in hypothalamic connectivity.
- Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes.
- GLP-1 Receptor Agonist Exenatide Attenuates the Detrimental Effects of Obesity on Inflammatory Profile in Testis and Sperm Quality in Mice.
- Association among weight change, glycemic control, and markers of cardiovascular risk with exenatide once weekly: a pooled analysis of patients with type 2 diabetes.
- Treatment of clozapine-associated obesity and diabetes with exenatide in adults with schizophrenia: A randomized controlled trial (CODEX).
- A 6-month randomized, double-blind, placebo-controlled trial of weekly exenatide in adolescents with obesity.
- Effects of exenatide on weight and appetite in overweight adolescents and young adults with Prader-Willi syndrome.
- Weight-related quality of life, health utility, psychological well-being, and satisfaction with exenatide once weekly compared with sitagliptin or pioglitazone after 26 weeks of treatment.
- Exenatide acutely increases heart rate in parallel with augmented sympathetic nervous system activation in healthy overweight males.
- Exenatide therapy in insulin-treated type 2 diabetes and obesity.
- Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year.
- Gender-related different effects of a combined therapy of Exenatide and Metformin on overweight or obesity patients with type 2 diabetes mellitus.